SCHEMBL31036634

SCHEMBL31036634

CCN(CCBr)CCOCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 3/20 0.47
KCNH2 Q12809 3/20 0.47
CHRM2 P08172 3/20 0.47
CHRM1 P11229 3/20 0.47
DRD1 P21728 2/20 0.47
HTR1A P08908 1/20 0.47
ADRA2A P08913 1/20 0.47
SLC6A2 P23975 1/20 0.47
SLC6A4 P31645 1/20 0.47
ADRA1A P35348 1/20 0.47
OPRM1 P35372 1/20 0.47
SLC6A3 Q01959 1/20 0.47
CYP1A2 P05177 1/20 0.46
LTA4H P09960 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
HTT P42858 1/20 0.46
TSHR P16473 1/20 0.45
DRD2 P14416 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2431466 0.90 CYP1A2 (0.56) DRD3KCNH2CHRM2CHRM1DRD1
SCHEMBL12531323 0.85 DRD1 (0.46) DRD3KCNH2CHRM2CHRM1DRD1
SCHEMBL31036611 0.83 TSHR (0.46) DRD3KCNH2CHRM2CHRM1DRD1
SCHEMBL30997661 0.81 TSHR (0.56) DRD3KCNH2CHRM2CHRM1DRD1
SCHEMBL13136746 0.81 TSHR (0.56) DRD3DRD1OPRM1TSHRDRD2
SCHEMBL21172037 0.79 KCNH2 (0.55) DRD3KCNH2CHRM2CHRM1DRD1
SCHEMBL12198807 0.77 TSHR (0.56) CYP1A2LTA4HCYP2D6CYP2C9CYP2C19
SCHEMBL4505794 0.77 TSHR (0.50) CHRM2CHRM1HTTTSHR
SCHEMBL11465304 0.77 TSHR (0.54) OPRM1LTA4HTSHRBCHEL3MBTL1
SCHEMBL146520 0.76 TSHR (0.64) LTA4HHTTTSHRKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4682138-A1 COMPOUND OR SALT THEREOF, LIPID COMPOSITION, PHARMACEUTICAL COMPOSITION, AND DELIVERY CARRIER FUJIFILM Corporation (JP) 2026-01-21 EP disclosed
US-20260001834-A1 COMPOUND OR SALT THEREOF, LIPID COMPOSITION, PHARMACEUTICAL COMPOSITION, AND DELIVERY CARRIER FUJIFILM CORPORATION (JP) 2026-01-01 US disclosed
WO-2024190817-A1 COMPOUND OR SALT THEREOF, LIPID COMPOSITION, PHARMACEUTICAL COMPOSITION, AND DELIVERY CARRIER 富士フイルム株式会社 2024-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001834-A1 COMPOUND OR SALT THEREOF, LIPID COMPOSITION, PHARMACEUTICAL COMPOSITION, AND DELIVERY CARRIER NSUN3, NPC1L1, TLR9 DRD3 2499/4885KCNH2 3732/4885CHRM2 4298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.